5 Drugs Stocks Dragging The Industry Down

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 3 points (0.0%) at 16,165 as of Thursday, Dec. 19, 2013, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,090 issues advancing vs. 1,843 declining with 148 unchanged.

The Drugs industry currently sits up 0.5% versus the S&P 500, which is down 0.2%. A company within the industry that fell today was Valeant Pharmaceuticals International ( VRX), up 1.1%. A company within the industry that increased today was Novo Nordisk A/S ( NVO), up 2.1%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Perrigo Company ( PRGO) is one of the companies pushing the Drugs industry lower today. As of noon trading, Perrigo Company is down $4.48 (-2.9%) to $151.07 on average volume. Thus far, 773,870 shares of Perrigo Company exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $150.63-$155.55 after having opened the day at $155.31 as compared to the previous trading day's close of $155.55.

Perrigo Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Perrigo Company has a market cap of $14.5 billion and is part of the health care sector. The company has a P/E ratio of 32.3, above the S&P 500 P/E ratio of 17.7. Shares are up 49.6% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Perrigo Company a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Perrigo Company as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Perrigo Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Regeneron Pharmaceuticals ( REGN) is down $6.17 (-2.3%) to $265.55 on light volume. Thus far, 261,086 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 756,100 shares. The stock has ranged in price between $264.35-$270.95 after having opened the day at $270.17 as compared to the previous trading day's close of $271.72.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $25.5 billion and is part of the health care sector. The company has a P/E ratio of 36.6, above the S&P 500 P/E ratio of 17.7. Shares are up 58.8% year to date as of the close of trading on Wednesday. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Eli Lilly and Company ( LLY) is down $0.52 (-1.0%) to $50.00 on light volume. Thus far, 2.0 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 6.5 million shares. The stock has ranged in price between $49.89-$50.51 after having opened the day at $50.37 as compared to the previous trading day's close of $50.51.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $55.5 billion and is part of the health care sector. The company has a P/E ratio of 11.2, below the S&P 500 P/E ratio of 17.7. Shares are up 2.4% year to date as of the close of trading on Wednesday. Currently there are 5 analysts that rate Eli Lilly and Company a buy, 2 analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Biogen Idec ( BIIB) is down $4.12 (-1.5%) to $276.52 on light volume. Thus far, 345,274 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $275.17-$280.43 after having opened the day at $278.88 as compared to the previous trading day's close of $280.64.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $64.1 billion and is part of the health care sector. The company has a P/E ratio of 38.1, above the S&P 500 P/E ratio of 17.7. Shares are up 85.5% year to date as of the close of trading on Wednesday. Currently there are 15 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Idec Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Amgen ( AMGN) is down $0.86 (-0.8%) to $111.87 on average volume. Thus far, 1.2 million shares of Amgen exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $110.92-$112.64 after having opened the day at $112.55 as compared to the previous trading day's close of $112.73.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $83.7 billion and is part of the health care sector. The company has a P/E ratio of 17.6, below the S&P 500 P/E ratio of 17.7. Shares are up 28.8% year to date as of the close of trading on Wednesday. Currently there are 8 analysts that rate Amgen a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers